Physician profile
Michael S Kenly
NPI 1548445307
$7,332.82
in general payments reported to CMS, 2019-2025
15 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 91% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $209 · 2021: $834 · 2022: $678 · 2023: $805 · 2024: $2,730 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,124 · Travel and Lodging: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,124.28 |
| Travel and Lodging | $824.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,713.15 | 2019-2025 | General - Pain Management, Intracept |
| Nevro Corp. | $1,847.83 | 2019-2024 | Senza |
| Biotronik Nro, INC. | $1,023.06 | 2023-2025 | Prospera, Biotronik |
| Abbott Laboratories | $312.49 | 2019-2025 | Eterna |
| Vertex Pharmaceuticals Incorporated | $85.76 | 2025 | |
| Bioventus LLC | $72.71 | 2019-2020 | |
| Stryker Corporation | $60.43 | 2023 | Variax, Augment Injectable, Gamma |
| Vertiflex, INC. | $48.05 | 2019 | |
| Team_makena_llc | $46.29 | 2021 | |
| Vericel Corporation | $31.16 | 2019 | |
| Medtronic USA, INC. | $30.09 | 2020 | |
| Almatica Pharma LLC | $18.69 | 2025 | Teriparatide |
| Pfizer INC. | $15.34 | 2019 | |
| Djo, LLC | $14.53 | 2019 | |
| Medtronic, INC. | $13.24 | 2023 | Vanta Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kenly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.